Mineralys Therapeutics, Inc. SEC Filings

Mineralys Therapeutics, Inc. (MLYS) reported insider activity on a Form 4. The company’s Chief Executive Officer and director sold 200,000 shares of common stock on 11/11/2025 in multiple transactions at weighted‑average prices that include $41.6395, $42.3095, $43.4959, $45.2003, $45.8335, and $46.8862. Footnotes disclose execution price ranges spanning $41.0500 to $47.4191 for the respective trades.

After these sales, the reporting person beneficially owns 631,305 shares, held directly. This filing lists the transactions as open‑market sales with weighted‑average pricing and provides to interested parties the availability of detailed trade‑by‑trade breakdowns upon request.

Mineralys Therapeutics (MLYS) director reports option exercise and same-day sales. On 11/13/2025, the reporting person exercised 15,000 stock options at $10.20 per share, received 15,000 common shares, and sold them in two tranches at weighted-average prices of $45.8083 and $46.3554.

The sales totaled 10,115 shares at $45.8083 and 4,885 shares at $46.3554, resulting in 0 common shares held directly after the transactions. Following the exercise, 17,900 stock options remained beneficially owned, with the option grant expiring on 02/13/2035 and vesting in 12 monthly installments following the grant date.

Mineralys Therapeutics director reports option exercises and share sales. A company director filed a Form 4 showing multiple stock option exercises on November 11–13, 2025 at exercise prices of $10.20 and $12.69 per share, followed by same-day open market sales of the resulting common shares at prices around $42.43–$47.28.

After these transactions, the reporting person held no shares of common stock directly, but continued to hold 34,000 stock options with exercise prices of $10.20 and $12.69, expiring in 2034 and 2035 and vesting in monthly installments.

Mineralys Therapeutics (MLYS) filed its third‑quarter 2025 report, highlighting progress toward an NDA for lorundrostat and a strengthened balance sheet. The company completed two pivotal hypertension trials (Launch‑HTN and Advance‑HTN) that achieved statistical significance and plans to submit an NDA in late 2025 or during the first quarter of 2026.

Cash, cash equivalents, and investments totaled $593.6 million as of September 30, 2025. For the quarter, basic and diluted net loss per share was $0.52. For the nine months ended September 30, 2025, net loss was $122.4 million.

Mineralys raised capital through two underwritten offerings—$269.6 million in September 2025 and $188.7 million in March 2025—and an ATM program totaling $27.3 million in net proceeds before terminating the ATM in November 2025. These funds support clinical development, manufacturing, pre‑commercialization, and general corporate purposes. Common shares outstanding were 79,139,956 as of November 3, 2025.

Mineralys Therapeutics, Inc. filed an 8‑K stating it issued a press release announcing financial results for the quarter ended September 30, 2025 and provided a corporate update. The press release is furnished as Exhibit 99.1.

Consistent with Item 2.02 treatment and General Instruction B.2, the information, including Exhibit 99.1, is furnished and not deemed filed or subject to Section 18 liabilities, and is not incorporated by reference except as specifically set forth.

Mineralys Therapeutics (MLYS) reported insider activity: its CFO and Secretary sold common stock in two open‑market transactions on 10/13/2025 under a Rule 10b5-1 trading plan adopted on November 14, 2023.

The sales covered 7,366 shares at a weighted‑average price of $41.9021 and 3,392 shares at a weighted‑average price of $42.2561. Following these transactions, the reporting person beneficially owned 116,865 shares. The filing notes that 5,311 shares were previously transferred to an ex‑spouse pursuant to a domestic relations order.

Mineralys Therapeutics (MLYS) disclosed insider sales by its Chief Executive Officer and director on 10/13/2025. The CEO sold 13,548 shares at a weighted-average price of $42.6295 (range $41.9800–$42.9800) and 1,552 shares at a weighted-average price of $43.0299 (range $42.9822–$43.2030) pursuant to a Rule 10b5-1 trading plan adopted on January 30, 2024. Following these transactions, the reporting person directly beneficially owned 831,305 shares.

Mineralys Therapeutics (MLYS) insider activity: The company’s Chief Medical Officer sold 10,369 shares of common stock on 10/15/2025 in an open-market transaction coded “S.” The sale was executed under a Rule 10b5-1 trading plan adopted on October 25, 2024.

The weighted-average price was $43.0111 per share, with individual trades ranging from $42.8000 to $43.1950. Following the transaction, the officer directly beneficially owns 71,155 shares.

Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), reported two open-market sales of company common stock on 09/15/2025 under a Rule 10b5-1 trading plan adopted on October 25, 2024. He sold a total of 11,367 shares in multiple transactions: 9,302 shares at a weighted-average price of $35.9004 and 2,065 shares at a weighted-average price of $36.4748. The filings show the sales occurred at prices within ranges of $35.4000–$36.3955 and $36.4026–$36.7005 respectively, and the reporting person is left with 83,589 and then 81,524 shares beneficially owned following each reported transaction. The Form 4 was signed by an attorney-in-fact on 09/16/2025.